Xiqi Peng
Overview
Explore the profile of Xiqi Peng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tang S, Tang D, Zhou H, Li Y, Zhou D, Peng X, et al.
Proc Natl Acad Sci U S A
. 2024 Jul;
121(30):e2403460121.
PMID: 39008666
Autonomous nanorobots represent an advanced tool for precision therapy to improve therapeutic efficacy. However, current nanorobotic designs primarily rely on inorganic materials with compromised biocompatibility and limited biological functions. Here,...
2.
Tang D, Peng X, Wu S, Tang S
Nanomaterials (Basel)
. 2024 Apr;
14(7).
PMID: 38607129
Artificial nanorobots have emerged as promising tools for a wide range of biomedical applications, including biosensing, detoxification, and drug delivery. Their unique ability to navigate confined spaces with precise control...
3.
Li Y, Cong Z, Xie L, Tang S, Ren C, Peng X, et al.
Small
. 2023 Jun;
19(42):e2301489.
PMID: 37300342
Motile microrobots open a new realm for disease treatment. However, the concerns of possible immune elimination, targeted capability and limited therapeutic avenue of microrobots constrain its practical biomedical applications. Herein,...
4.
Peng X, Tang S, Tang D, Zhou D, Li Y, Chen Q, et al.
Sci Adv
. 2023 Jun;
9(23):eadh1736.
PMID: 37294758
Nanorobotic manipulation to access subcellular organelles remains unmet due to the challenge in achieving intracellular controlled propulsion. Intracellular organelles, such as mitochondria, are an emerging therapeutic target with selective targeting...
5.
Li X, Chen W, Li R, Chen X, Huang G, Lu C, et al.
Future Oncol
. 2022 Sep;
18(29):3311-3322.
PMID: 36047424
Bladder cancer is one of the most prevalent malignancies. Due to the disadvantage of existing bladder cancer diagnostic tools, miRNAs hold promise as new diagnostic markers. A total of 224...
6.
Li R, Xia Y, Chen X, Li X, Huang G, Peng X, et al.
Transl Cancer Res
. 2022 Jun;
11(5):1005-1016.
PMID: 35706801
Background: Bladder cancer (BC) is the tenth most common cancer in the world. Serum microRNA (miRNA) profiles previously have been reported as non-invasive biomarkers in cancer screening. The non-invasive and...
7.
Li R, Lu C, Yang W, Zhou Y, Zhong J, Chen X, et al.
J Clin Lab Anal
. 2022 Jan;
36(2):e24194.
PMID: 35028969
Background: Nasopharyngeal carcinoma is cancer with unique epidemiological characteristics, showing obvious ethnicity, gender, and geographical prevalence. More and more evidence shows that microRNAs are stable in serum and are specific...
8.
Wang J, Peng X, Li R, Liu K, Zhang C, Chen X, et al.
Front Oncol
. 2022 Jan;
11:795837.
PMID: 35004321
Previous studies have shown that the miR-17-92 cluster is involved in the occurrence and development of bladder cancer. However, the role of serum miR-17-92 cluster in the diagnosis of bladder...
9.
Chen X, Li R, Li X, Peng X, Zhang C, Liu K, et al.
Pathol Res Pract
. 2021 Oct;
227:153625.
PMID: 34628264
Background: The aim of the study was to identify serum microRNAs (miRNAs) as potential biomarkers for screening renal cell carcinoma. Methods: The study was divided into three stages, including screening...
10.
Chen X, Li X, Wang J, Zhao L, Peng X, Zhang C, et al.
Biomark Med
. 2021 Jul;
15(12):951-963.
PMID: 34293926
Breast cancer, especially invasive ductal carcinoma (IDC), is the cause of a great clinical burden. miRNA could be considered as a noninvasive biomarkers for IDC diagnosis. Two hundred and sixty...